Drug Pricing Pharmaceutical Companies Pharmaceutical Manufacturing 
Pharmaceutical Commerce
JUNE 17, 2025
Structuring patient assistance programs as independent non-profit foundations helps pharmaceutical companies reduce regulatory and legal exposure while allowing for more holistic, patient-centered support. Lastly, PAPs that are directly managed by pharmaceutical companies may also struggle with public image issues.
Pharmaceutical Technology
NOVEMBER 21, 2022
However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
HealthPartners
MAY 5, 2021
Ultimately, this insight can help ensure your company and your employees are getting the greatest value from your pharmacy benefits plan. Understanding pharmacy benefit management and drug pricing The U.S. prescription drug supply chain is extraordinarily complex. To better understand it, see the below diagram.
Pharmaceutical Technology
NOVEMBER 21, 2022
However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.
Pharmaceutical Commerce
JUNE 17, 2025
AI in value-based pricing and RWE generation AI has the potential to transform value-based pricing (VBP) by leveraging machine learning for dynamic pricing models that adjust drug prices based on real-world patient outcomes.
European Pharmaceutical Review
NOVEMBER 8, 2022
In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.
Viseven
JANUARY 13, 2023
Evaluation of drug efficiency on a dedicated market is a complex process that requires HEOR experts to measure multiple indicators to understand the actual market value of the product. So what do exactly HEOR experts do for the pharmaceutical companies and what HEOR-collected data is used for? What is HEOR Data?
Expert insights. Personalized for you.
59 
Let's personalize your content